Takeda Pharmaceutical has agreed to acquire Nycomed, a Swiss pharmaceutical company for $13.5 billion, excluding Nycomed's US dermatology business. The deal is intended to increase Takeda's presence in European and emerging markets.
Takeda Pharmaceutical has agreed to acquire Nycomed, a Swiss pharmaceutical company for €9.6 billion ($13.7 billion), excluding Nycomed’s US dermatology business. The deal is intended to increase Takeda’s presence in European and emerging markets.
Nycomed had overall sales of nearly €3.2 billion ($4.5 billion) in fiscal year 2010, and sales of €2.8 billion ($3.9 billion) when excluding its US dermatology business. It is a privately held Zurich-based pharmaceutical company with prescription and over-the-counter products. The acquisition includes the roflumilast franchise, a treatment for chronic obstructive pulmonary disease, which Takeda expects will be a “major source of revenue growth,” according to a May 19, 2011, Takeda press release. Overall, Takeda expects the acquisition to increase its annual revenue by 30%.
The boards of directors of Takeda and Nycomed have agreed to the transaction, as have the shareholders of Nycomed. The deal is expected to close within 90 to 120 days, subject to antitrust approval. Upon closing, Nycomed will become a subsidiary of Takeda. Nycomed is currently owned by the private-equity group Nordic Capital and other investors.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.